Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY(2015)
摘要
AimThis systematic review and meta-analysis was performed to assess the efficacy and side effects between single-agent and doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2 (PS2). MethodsWe searched for randomized controlled trials in online electronic databases and extracted data from eligible studies for meta-analysis. Pooled hazard ratio (HR) for overall survival (OS), pooled risk difference (RD) for 1-year survival, pooled risk ratio (RR) for objective response rate (ORR) and adverse effects were calculated using a fixed-effect model. ResultsSix trials with 386 participants in the single-agent group and 389 participants in the doublet group were included in this review. Compared with single-agent chemotherapy, doublet significantly improved OS (HR 0.72; 95% CI 0.61-0.84; P<0.0001) and significantly increased 1-year survival rate (RD -0.09; 95% CI -0.14 to -0.03; P=0.004) and ORR (RR 0.4; 95% CI 0.30-0.69; P=0.0002). Doublet chemotherapy also significantly increased the risk of grade 3/4 neutropenia (RR=4.97; 95% CI 2.93-8.43; P<0.00001), thrombocytopenia (RR=10.29; 95% CI 3.80-27.85; P<0.00001) and anemia (RR=2.50; 95% CI 1.27-4.90; P=0.008). ConclusionsOur study implies that carboplatin-containing doublet chemotherapy improved OS, 1-year survival rate and ORR, but increased the risk of grade 3/4 hematotoxicity. Carboplatin-containing doublet may well be superior to non-carboplatin-containing treatment.
更多查看译文
关键词
doublet,meta-analysis,non-small cell lung cancer,performance status 2,single agent
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络